GlassScriptPhysician profile
Joseph W Warren
NPI 1952394058
$4,767.29
in general payments reported to CMS, 2019-2025
39 companies · $874 in 2025
The $874 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $362 · 2021: $402 · 2022: $882 · 2023: $884 · 2024: $717 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.50 |
| Education | $247.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $874.18 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $396.50 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $308.10 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $281.40 | 2020-2025 | Acthar, Terlivaz |
| Baxter Healthcare | $266.92 | 2019-2023 | |
| Reddress USA, INC. | $266.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $250.62 | 2019-2025 | Farxiga, Lokelma |
| Xeris Pharmaceuticals, INC. | $203.30 | 2021-2025 | Keveyis |
| Amgen INC. | $202.85 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Mallinckrodt Enterprises LLC | $155.13 | 2019 | |
| Calliditas Therapeutics US INC. | $144.40 | 2022-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $134.55 | 2024-2025 | |
| Glaxosmithkline, LLC. | $131.09 | 2021-2024 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $113.26 | 2020-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $106.74 | 2021-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $104.52 | 2021-2024 | Vafseo |
| Fresenius USA Marketing, INC. | $86.94 | 2022-2024 | Velphoro |
| American Regent | $80.13 | 2023 | Injectafer |
| Leadiant Biosciences, INC. | $65.63 | 2022-2025 | Cystaran |
| Ardelyx, INC. | $63.44 | 2024 | Ibsrela |
| Recordati_rare_diseases_inc. | $60.78 | 2022 | |
| Eusa Pharma (US) LLC | $60.77 | 2022 | |
| Aurinia Pharma U.S., INC. | $52.73 | 2022-2024 | Lupkynis |
| Octapharma USA, INC. | $46.03 | 2019-2020 | |
| Kyowa Kirin, INC. | $34.59 | 2023 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $32.90 | 2019-2020 | |
| Novo Nordisk INC | $31.09 | 2023 | Ozempic |
| Renalytix Ai, INC. | $22.48 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Cycle Pharmaceuticals INC | $21.28 | 2024 | Tiopronin |
| Merck Sharp & Dohme LLC | $20.85 | 2024 | Prevymis |
| Alnylam Pharmaceuticals INC. | $20.83 | 2023 | Givlaari |
| Lilly USA, LLC | $19.81 | 2025 | Jardiance |
| Amicus Therapeutics, INC. | $17.66 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.11 | 2022 | |
| Nuwellis, INC. | $15.62 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.44 | 2019 | |
| Strongbridge US INC. | $14.39 | 2020 | |
| Avion Pharmaceuticals | $13.88 | 2020 | |
| Daxor Corporation | $13.56 | 2024 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.